COLLABORATION WITH THE TRANSLATIONAL RESEARCH UNIT OF THE DE INSTITUT CATALÀ D’ONCOLOGIA (ICO) DE GIRONA ( CATALAN INSTITUT OF ONCOLOGY)
In 2008 they began several lines of investigation the result of collaboration between the Translational Research Unit of the ICO Girona and Service Pathological of the Hospital Universitari de Girona Doctor Josep Trueta. These research projects co-directed by Dr. Javier A. Menéndez, head of Translational Research Unit of the ICO Girona and by Dr. Eugeni López Bonet of the Pathology service of the Hospital Universitari de Girona Doctor Josep Trueta. This This collaboration has fructified in the form of publications in prestigious international journals,lectures and presentations at international conferences and preparation of doctoral theses.
The lines of research begun with their productions are:
Sensors in the metabolic process of mitosis of tumor cells : molecular description, evaluation and clinical relevance :
-
Interaction between active state of kinase activated by monophosfat of adenine (P-AMPK) at M of the cell cycle of tumor cells.
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor.
Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA.
Cell Cycle. 2009 Nov 15;8(22):3679-83.
Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKαThr172) in human cancer cells.
Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L, Menendez JA.
Cell Cycle. 2009 Mar 1;8(5):788-91.
Descubrimiento y validación de Fosfo-AMPKa-Thr172 como marcador de mitosis en el carcinoma de mama: impact on histological grade.
Doctoral thesis by Eugeni López Bonet of Pathological service of the Hospital Universitari de Girona Doctor Josep Trueta, co-directedby Drs. J.A. Menéndez i Santiago Ramón y Cajal on 10 february 2012 and approved cum laude at the Universitat Autònoma de Barcelona.
Descubrimiento y validación de nuevos marcadores de mitosis en el carcinoma de mama: impact on histological grade.
Memòria presentada per Eugeni López Bonet del Servei d’Anatomia Patològica de l’Hospital Universitari de Girona Doctor Josep Trueta el 23 d’Octubre de 2010 a Madrid per a l’obtenció del títol de Master en Oncologia Molecular pel Centro Nacional de Investigaciones Oncológicas.
-
Cellular location of form self phosphorylated of mammalian target of rapamycin (P-mTOR) and kinase phosphorilated p70S6 (P-S6K1) tumor cell division.
Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies.
Lopez-Bonet E, Vazquez-Martin A, Pérez-Martínez MC, Oliveras-Ferraros C, Pérez-Bueno F, Bernadó L, Menendez JA.
Int J Oncol. 2010 Jan;36(1):107-15.
The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells.
Vazquez-Martin A, Oliveras-Ferraros C, Bernadó L, López-Bonet E, Menendez JA.
Biochem Biophys Res Commun. 2009 Mar 13;380(3):638-43.
Monitoring autophosphorylation of mammalian target of rapamycin (mTOR) for histoprognostic grading of invasive breast cancer: impact on the reclassification of patients with grade 2 tumors using the Nottingham grading system.
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
San Antonio Breast Cancer Symposium December 7, 2011,
Monitoring Phosphorylation of p70S6K1 Kinase (Thr421/Ser424), a Biological Marker for mTOR Activity, improves Nottingham Histoprognostic Grading of Invasive Breast Carcinomas.
Sauri-Nadal T, Del Barco S, Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
5th EORTC Annual Meeting on Molecular Markers in Cancer. Brussels, Belgium 27-29 October 2011.
Immunohistochemical analysis of the serine 2481-autophosphorylated form of mammalian target of rapamycin: a novel high-contrast mitosis marker in breast cancer core biopsies.
E. Lopez-Bonet, A. Vazquez-Martin, M.C. Perez-Martinez, C. Oliveras-Ferraros, F. Perez-Bueno, L. Bernadó, J.A. Menendez.
IMPAKT Breast Cancer Conference. Brussels, 7-9 May 2009.
Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cytokinesis.
Vazquez-Martin A, Sauri-Nadal T, Menendez OJ, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, López-Bonet E, Menendez JA.
Cell Cycle.2012 Nov15;11(22):4211-21.
Interactions and resistence mechanisms of antibodies against the Epidermal Growth Factor HER1 i HER2 receptors.
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin AG, Menendez JA.
Cell Cycle. 2012 Nov1;11(21):4020-32.
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA.
Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9.
Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Del Barco S, López-Bonet E, Menendez JA.
Genes Chromosomes Cancer. 2011 Apr;50(4):284-90.
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.
Int J Oncol. 2010 Sep;37(3):669-78.
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.
Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33.
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
Int J Oncol. 2008 Dec;33(6):1165-76.
Genetic ablation or pharmacological inhibition of autophagy suppresses intrinsic resistance of breast cancer to HER2-targeted therapies.
Cufí S, Oliveras-Ferraros C, Vazquez-Martin A, Sauri-Nadal T, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
San Antonio Breast Cancer Symposium December 7, 2011.
Introduction of antidiabetic drug metformina in the treatment of breast carcinoma .
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.
Oncol Rep. 2011 Jan;25(1):135-40.
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA.
Ann Oncol. 2010 Jan;21(1):187-9.
Immunohistochemical study of primary neuroendocrine carcinoma of the breast.
Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
Lopez-Bonet E, Pérez-Martínez MC, Martin-Castillo B, Alonso-Ruano M, Tuca F, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Beltràn M, Bernadó L, Menendez JA.
Breast Cancer Res Treat. 2011 Feb;126(1):241-5.
Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA.
Oncol Rep. 2008 Dec;20(6):1369-74.
Modeling tumor Stem cells
Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the 'self (stem cell)-seeding' nature of breast cancer disease?
Lopez-Bonet E, Menendez JA.
Ann Oncol. 2010 Apr;21(4):901-2.
"Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
Vazquez-Martin A, Cufí S, López-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin-Castillo B, Menendez JA.
Sci Rep.2012;2:964.
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martrin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín AG, López-Bonet E, Menendez JA.
Cell Cycle.2013 Jan 15;12(2):225-45.
The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells.
Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A.
Cell Cycle. 2013 Apr 15;12(8):1166-79.
OTHER PUBLICATIONS WHO HAVE PARTICIPATED MEMBERS OF PATHOLOGY SERVICE (2010-2013)
Impacto de la obesidad en las caraterísticas anatomopatológicas de los tumores colorrectales. Estudio observacional.
Garcia-Oria MJ, Armengol M, Ortiz R, Codina-Cazador A.
Cir Esp. 2010;87(1):33-8.
Antimicrobial cyclic decapeptides with anticancer activity.
Feliu L, Oliveras G, Cirac AD, Besalú E, Rosés C, Colomer R, Bardaji E, Planas M, Puig T.
Peptides 2010Nov;31(11):2017-26.
Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer.
Oliveras G, Blancafort A, Urruticoechea A, Campuzano O, Gómez-Cabello D, Brugada R, López-Rodríguez ML, Colomer R, Puig T.
Ann NY Acad Sci. 2010Oct;1210:86-92
Epidemiologia del cáncer de cérvix in situ e invasor en la provincia de Girona 1990-2004: incidencia, mortalidad, supervivencia e historial de cribado.
Castro P, Moreno- Crespi J, Buxó M, Cervantes M, Pérez-Gómez B, Marcos-Gragera R.
Med Clin(Barc). 2011Feb;136(5):192-198.
Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.
Fuentes-Raspall R, Vilardell L, Pérez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, Marcos-Gragera R.
J Neurooncol. 2011Jan;101(1):117-23.
Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma.
Puig-Costa M, Oliveras-Ferraros C, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Martin-Castillo B, Vazquez-Martin A, Cufí S, Ortiz R, Roig J, Codina-Cazador A, Menéndez JA.
J Surg Oncol. 2011Jul;104(1):106-9.
Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994-2004.
Alsina M, Marcos-Gragera R, Capdevila J, Buxó M, Ortiz MR, Barretina P, Vilardell L, Brunet J, Beltran M, Izquierdo A.
Cancer Epidemiology 2011;35:49-54.
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R.
Breast Cancer Res. 2011Dec;13(6):R131.
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinoma: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, López-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA.
Int J Oncol. 2011Dec;39(6):1455-79.
Perfomance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based linear array.
Godínez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, Bravo IG, Bosch FX, De Sanjose S.
Infec Agent Cancer 2011;6:23.
Prediccion of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of unetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, De Sanjosé S.
BMC Infec Dis. 2012;12:25.
Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study.
Bernet L, Rojo F, Hardisson D, Córdoba A, Panadés MJ, Velasco A, López-Bonet E, Cano R, Polo L.
Diagn Mol Pathol. 2012Jun;21(2):69-76.
New synthetic inhibitors of fatty acid synthase with anticancer activity.
Turrado C, Puig T, Garcia-Cárceles J,Artola M, Benhamú B, Ortega-Gutiérrez S, Relat J, Oliveras G, Blancafort A, Haro D, Marrero PF, Colomer R, López-Rodríguez ML.
J Med Chem. 2012Jun;55(11):5013-23.
Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in adenocarcinoma lung cancer.
Relat j, Blancafort A, Oliveras G, Cufí S, Haro D, Marrero PF, Puig T.
BMC Cancer 2012Jul;12(1):280.
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A.
Int J Oncol.2012Sep;41(3):1128-38.
Quiz page August 2012: a man with nephrotic syndrome and a mediastinal mass.
Faur D, Martín N, Archuleta JM, Torguet P.
Am J Kidney Dis. 2012 Aug;60(2):A25-7.
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents.
Menendez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltán-Debón R, Borrás-Linares I, Camps J, Corominas-Faja B, Cufí S, Fernández-Arroyo S, Garcia-Heredia A, Hernández-Aguilera A, Herranz-López M, Jiménez-Sánchez C, López-Bonet E, Lozano-Sánchez J, Luciano-Mateo F, Martin-Castillo B, Martin-Paradero V, Pérez-Sánchez A, Oliveras-Ferraros C, Riera-Borrull M, Rodríguez-Gallego E, Quirantes-Piné R, Rull A, Tomás-Menor L, Vazquez-Martin A, Alonso-Villaverde C, Micol V, Segura-Carretero A.
Cell Cycle. 2013 Feb 15;12(4):555-78.
A diagnosic approach to the mediastinal masses.
Juanpere S, Cañete N, Ortuño P, Martínez G, Bernadó L
Insights Imaging. 2013Feb;4(19):29-52.
Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature.
Alonso-Ruano M, López-Bonet E, Huerta-Anaya MV, Vila-Camps E, Bernadó L, Tuca-Rodríguez F, Suarez-Pumariega P, Menendez JA.
Oncol Lett. 2013Feb;5(2):459-462.
Albuminin-binding MR blood pool contrast agent improves diagnosic performance in human brain tumour: comparison of two contrast agents for glioblastoma.
Puig J, Blasco G, Essig M, Daunis-I-Estadella J, Laguillo G, Quiles AM, Remollo S, Bergmann K, Joly C, Bernadó L, Sánchez-González J, Pedraza S.
Eur Radiol. 2013Apr;23(4):1093-101.
α2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues.
Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolos C, Figueras J, de Llorens R, Vidal-Vanaclocha F, Peracaula R.
Int J Biochem Cell Biol. 2013May28. doi:pii: S1357-2725(13)00152-O. 10.1016/j.biocel.2013.05.015.(Epub ahead of print).